Letter to the editor concerning the article ‘Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and meta-analysis’ (JAMA Netw Open. 2019;2(10):e1912458)

Bernd Benninghoff ☞, Priya Pereira ☞, and Corinne Willame ☞

GSK Vaccines, Wavre, Belgium

A recent meta-analysis investigating the association between intussusception (IS) and rotavirus (RV) vaccination demonstrated an absence of risk up to 2 years after vaccination. Meta-analyses including only randomized clinical trials are inadequate to identify a potential increased risk of rare adverse events such as IS. The study conducted failed to discuss relevant limitations. Additionally, the safety profiles of newer RV vaccines, evaluated in clinical studies with limited sample size, were considered comparable with that of the well-established and widely used RV vaccines, RotaTeq and Rotarix. We, therefore, re-emphasize that extensive and updated evidence from post-marketing surveillance indicates a slight increased risk of IS, mostly within 7 days of RV vaccination, with a benefit/risk profile assessment in favor of RV vaccination.

1. A Meta-analysis including only randomized clinical trials (RCTs) to assess rare safety events for RV vaccines is erroneous

While common adverse events are identified during clinical development phases, rare adverse events such as IS in case of RV vaccination may go undetected or unconfirmed until post-marketing use. Post-marketing evaluation and passive surveillance are needed to detect rare adverse events or association with diseases that have low incidences. Such safety evaluations have been previously requested by national health authorities as they provide strong evidence on the benefits and risks of real-world use of RV vaccines.

2. The conclusion statement “our results contradict the post-marketing monitoring suggestion about the risk of IS after RV vaccination” is incorrect

The scientific community and regulatory bodies largely acknowledge the increased risk of IS within a short interval after RV vaccination based on scientific methodological assessments. The increased risk of IS has been demonstrated in several large population-based studies. The authors missed to mention important limitations of their work, discussed below.

3. The review fails to highlight and discuss relevant limitations

Given the limited sample sizes, RCTs included in the meta-analysis were not powered to detect an increased risk of IS after RV vaccination. Limitations such as the power of RCTs with regards to safety endpoints, and the appropriate risk period to detect IS could have been discussed more appropriately. Furthermore, the authors criticized study designs for large population-based studies. However, these types of studies (i.e. cohort or self-controlled case series) are robust and accepted by regulatory bodies, such as the European Medicine Agency and the United States Food and Drug Administration, as methods for assessing the association between vaccines and outcome events. The main advantage of case-only designs is that it inherently controls for all non-time varying confounders.

4. Safety conclusion for newer vaccines is based on inadequate evidence

The meta-analysis included many RCTs for the 2 widely used vaccines (11 for Rotarix, 10 for RotaTeq) versus only 4 for the newer vaccines (i.e. 2 for Rotasili, 1 for Rotavac and 1 for the unlicensed vaccine, RV3BB). This is likely to introduce bias in the interpretation. Furthermore, the authors concluded positively on the favorable benefit/risk profile of the 3 newer RV vaccines. However, only large-scale use of these vaccines can justify this conclusion. RCTs conducted for the 3 newer

CONTACT Priya Pereira ☞ priya.p.pereira@gsk.com GSK, Avenue Fleming, 20, Wavre B1300, Belgium

© 2020 GlaxoSmithKline Biologicals SA. Published with license Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
vaccines were restricted to 1 or 2 countries/regions and hence the generalizability of the findings is not appropriate. To date, no evidence from post-marketing studies or from pharmacovigilance activities are available for these vaccines. As continuous post-marketing safety monitoring is required for a more robust vaccine assessment,7 the review provides an incomplete and inadequate positive safety conclusion for the newer vaccines. Moreover, it is not appropriate to conclude that the newer vaccines’ benefit/risk profile will be comparable to that of the 2 widely used RV vaccines based on the currently limited evidence.

5. The study generates miscommunication and potential risk to confidence in RV vaccination

Scientific publications discussing the safety profile of vaccines should provide reliable information and inform accordingly the scientific community and the public at large about the benefits and risks of vaccines. Key findings on the association of IS with RV vaccination were published 10 years ago6 and paved the way for vaccine use recommendations taking into consideration this risk.2–4 This well-accepted evidence was omitted from the discussion and interpretation of the meta-analysis’ results and should have been considered.

It is, therefore, our intention to re-emphasize that extensive and updated evidence from post-marketing surveillance indicates a slight increased risk of IS, mostly within 7 days of RV vaccination for both widely used vaccines, suggesting a class effect among RV vaccines.6 This safety concern has been carefully evaluated by the WHO Global Safety Evaluation Committee and the Centers for Disease Control and Prevention, with the conclusion that the benefit of the widely used RV vaccines largely outweigh this slight increased risk of IS.5 In the context of RV vaccination, it remains important to educate health-care practitioners of the rare occurrence of IS, and in addition, to make them aware that the consequences of IS can be better managed with parental counseling, early diagnosis and timely treatment.2,3 In fact, early vaccination may even help to reduce the risk of IS by avoiding an overlap with the peak period of natural IS onset.9

While we appreciate the authors’ efforts and interest in contributing with a meta-analysis to a current and relevant topic, real-world data should not be excluded when analyzing the benefit/risk balance of vaccination, especially when vaccine safety is discussed. We, therefore, consider it imperative to bring to the attention of the scientific community, as well as the public, that the paper may contain incomplete and inadequately interpreted information, leading to misinterpretation and therefore misleading conclusions.

Disclosure of potential conflicts of interest

GlaxoSmithKline Biologicals SA covered all costs associated with the development and publishing of the present letter. All authors are employees of the GSK group of companies. PP and BB hold shares in the GSK group of companies.

Trademark statement

Rotarix is a registered trademark owned by the GSK group of companies. RotaTeq is a registered trademark of Merck&Co, Inc. Rotavac is a registered trademark of Bharat Biotech. Rotasil is a registered trademark of Serum Institute of India Ltd.

References

1. Lu HL, Ding Y, Goyal H, Xu HG. Association between rotavirus vaccination and risk of intussusception among neonates and infants: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1912458. doi:10.1001/jamanetworkopen.2019.12458.
2. Global Advisory Committee on Vaccine Safety.6–7 December 2017 World Health Organization (WHO).Wkly Epidemiol Rec. 2018;93(2):17–30.
3. European Centre for Disease Prevention and Control. Expert opinion on rotavirus vaccination in infancy. 2017. [accessed 2019 Jan 3]. https://ecdc.europa.eu/sites/portal/files/documents/rotavirus-vaccination-expert%20opinion-september-2017.pdf.
4. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) summary report. Atlanta (Georgia); 2013 Jun 19–20 [accessed 2019 Dec 2]. http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf.
5. Clark A, Tate J, Parashar U, Jit M, Hasso-Agopowski M, Henschke N, Lopman B, Van Zandvoort K, Pecenka C, Fine P, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Glob Health. 2019;7(11):e1541–e52. doi:10.1016/s2214-109x(19)30412-7.
6. Rosillon D, Buyse H, Friedland LR, Ng SP, Velazquez FR, Breuer T. Risk of intussusception after rotavirus vaccination: meta-analysis of postlicensure studies. Pediatr Infect Dis J. 2015;34(7):763–68. doi:10.1097/inf.0000000000000715.
7. Lopalco PL, DeStefano F. The complementary roles of phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33(13):1541–48. doi:10.1016/j.vaccine.2014.10.047.
8. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. doi:10.1136/bmj.i4515.
9. Tate JE, Mwenda JM, Armah G, Jani B, Omore R, Ademe A, Mujuru H, Mpahalwane E, Ngwira B, Cortese MM, et al. Evaluation of intussusception after monovalent rotavirus vaccination in Africa. N Engl J Med. 2018;378(16):1521–28. doi:10.1056/NEJMoa1713909.